Medication Description: Phosphadenum (Phosphadenum)
Adenosine-5'-monophosphoric acid, or phosphoric ester of 9-b -D-ribofuranoside adenine.
Synonyms: Adenyl, Adenosine monophosphate, AMP, Adenil, Adenovite, Adenyl, AMP, Cardiomone, Fosfostimol, Monophosaden, Phosaden, Vitamin B8.
White crystalline powder; odorless. It is soluble in water, soluble in 1% solution of sodium bicarbonate.
Phosphaden (AMP) can be considered as a fragment of adenosine triphosphoric acid (ATP). AMP is a component of a number of coenzymes that regulate redox processes (See Flavinate, Cobamamide.). Participates in the normalization of porphyrin biosynthesis. It has a vasodilating effect. Possesses antiaggregatory properties.
Used in the treatment of acute intermittent porphyria and lead poisoning with severe polyneurotic syndrome, chronic obliterating endarteritis, thrombophlebitis, chronic venous insufficiency, venous thrombosis; sometimes with coronary heart disease.
There is evidence of improvement in the condition of patients with psoriasis in the treatment of phosphadenes, as well as patients with diabetic retinopathy.
In duodenal ulcer, an acceleration of the ulcer defect and a tendency to normalization of immunological parameters were noted (intramuscularly 1% solution, 5 ml, 2 times a day for 10–12 days). No significant effect on secretory and acid-forming functions was noted.
Apply phosphadenum inside tablets (regardless of the meal) and intramuscularly in the form of a solution of disodium salt.
In acute porphyria, it is administered first intramuscularly, starting with 0.06 g (3 ml of 2% solution) 5 times a day, gradually reducing the dose to 0.06 g 2 times a day, and then switching to taking the drug inside of 0.05 g 2 times a day; take a long time (depending on the condition of the patient).
For peripheral vascular diseases, intramuscular injection is prescribed in a dose of 0.04 g (2 ml of a 2% solution) 2 to 3 times a day (2 to 4 weeks), then inside 0.05 g 2 to 3 times a day.
In chronic ischemic heart disease, 0.04 g is injected intramuscularly 3-4 times a day for 25-30 days, then given orally by 0.05 g 4 times a day.
In other diseases, oral administration is prescribed at 0.025-0.05 g (up to 0.15 g per day) or intramuscularly at 0.02-0.04 g (up to 0.12 g per day) for 2-4 weeks.
In ophthalmic practice, phosphadena is administered orally at 0.05 g, 2 times a day, as well as in the form of retro-bulbar injections.
When taking phosphadena inside possible nausea, dizziness, tachycardia, allergic reactions; in these cases, reduce the dose or stop further use of the drug.
Method of production: tablets of 0.025 and 0.05 g in a package of 30 pieces or in cans of orange glass of 50 pieces; 2% solution for injection (Solutio Phosphadeni 2% of injectionibus; pH 6, 7-7, 5) in a package of 10 ampoules.
Storage: dry (tablets), protected from light.